Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문병인 | * |
dc.date.accessioned | 2021-07-08T16:32:21Z | - |
dc.date.available | 2021-07-08T16:32:21Z | - |
dc.date.issued | 2020 | * |
dc.identifier.issn | 0960-9776 | * |
dc.identifier.issn | 1532-3080 | * |
dc.identifier.other | OAK-28039 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/257792 | - |
dc.description.abstract | Purpose: Approval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world setting, we conducted a nationwide, multicenter, retrospective study. Methods: Patients with locally advanced or metastatic breast cancer who were treated with eribulin in 14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of 1.23 mg/m(2) (equivalent to 1.4 mg/m(2) eribulin mesylate) by intravenous infusion for 2-5 min, or as a diluted solution, on Days 1 and 8 of every 21-day cycle. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included median PFS, overall survival (OS), time-to-treatment failure (TTF), tumor response rate, and incidence of hematologic treatment-emergent adverse events (TEAEs). Results: The safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients, respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days, respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and 49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and anemia (11.3%) were most common. Conclusion: Real-world effectiveness and safety of eribulin in Korean breast cancer patients were consistent with previous reports; no new safety concerns were identified. (C) 2020 The Author(s). Published by Elsevier Ltd. | * |
dc.language | English | * |
dc.publisher | CHURCHILL LIVINGSTONE | * |
dc.subject | Eribulin mesylate | * |
dc.subject | Breast cancer | * |
dc.subject | Retrospective study | * |
dc.subject | Korean patients | * |
dc.title | A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK) | * |
dc.type | Article | * |
dc.relation.volume | 54 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 121 | * |
dc.relation.lastpage | 126 | * |
dc.relation.journaltitle | BREAST | * |
dc.identifier.doi | 10.1016/j.breast.2020.09.004 | * |
dc.identifier.wosid | WOS:000604437000018 | * |
dc.identifier.scopusid | 2-s2.0-85091503408 | * |
dc.author.google | Park, Min Ho | * |
dc.author.google | Lee, Soo Jung | * |
dc.author.google | Noh, Woo Chul | * |
dc.author.google | Jeon, Chang Wan | * |
dc.author.google | Lee, Seok Won | * |
dc.author.google | Son, Gil Soo | * |
dc.author.google | Moon, Byung-In | * |
dc.author.google | Lee, Jin Sun | * |
dc.author.google | Kang, Sung Soo | * |
dc.author.google | Suh, Young Jin | * |
dc.author.google | Gwak, Geumhee | * |
dc.author.google | Kim, Tae Hyun | * |
dc.author.google | Yoo, Young Bum | * |
dc.author.google | Kim, Hyun-Ah | * |
dc.author.google | Kim, Min Young | * |
dc.author.google | Kim, Ju Yeon | * |
dc.author.google | Jeong, Joon | * |
dc.contributor.scopusid | 문병인(7101878644;56119062300) | * |
dc.date.modifydate | 20231116123537 | * |